Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Elan Corporation, plc (ELN) -- Ignore unavailable to you. Want to Upgrade?

To: RCMac who wrote (3551)	11/13/2002 10:15:14 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 10345

As you know, I rarely take exception with Mike King. But..... 2001 sales of oxycontin were $1.2 billion. Given the fraction that is not due to abuse ($350 million?)..... has anyone in this thread yet given a reason that oxycontin is superior to avinza? If avinza can do 10% of oxycontin -- and I remain convinced that penetration of a fraction of the market can be rapid, due to the need to circumvent abuse -- then Ligand just walked with a HUGE bargain. 10% Heck, maybe someone has already rigged an abuse of avinza, and Ligand will do a billion after four years. :-( There was some heated discussion in this thread when this issue last reared. But I still don't remember any rationale that defined oxycontin as the preferred drug on the basis of efficacy.